Veradermics (MANE) EPS (Basic) (2025 - 2026)
Veradermics' (MANE) quarterly EPS (Basic) came in at -$1.32 in Q1 2026, up 93.32% YoY from -$0.68 in Q1 2025, and up 93.32% on a QoQ basis from -$19.79 in Q1 2025.
Powered by 
Analysis
Veradermics (MANE) EPS (Basic) (2025 - 2026) Analysis & Trends
Veradermics (MANE) has 2 years of EPS (Basic) data on file, last reported at -$1.32 in Q1 2026.
- Quarterly EPS (Basic) rose 93.32% year-over-year to -$1.32 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.96 (changed N/A YoY) and the FY2025 annual result came in at -$111.91, down 202.06% from the prior year.
- EPS (Basic) improved to -$1.32 in Q1 2026, from -$19.79 in the prior quarter.
- In the past five years, EPS (Basic) ranged from a high of -$1.32 in Q1 2026 to a low of -$19.79 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 7.70 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -1.96 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -3.06 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 2.12 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.23 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 0.18 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.06 |
| 10 | Veradermics | 3.96 Bn | 3.96 Bn | - | -0.58 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -0.58 |
| Mar 31, 2026 | -1.32 |
| Jun 30, 2025 | -24.19 |
| Mar 31, 2025 | -19.79 |